Biontech Se Sponsored Adr Stock News

WASHINGTON: Pfizer, BioNTech and Moderna are making combined profits of $65,000 every minute from their highly successful Covid-19 vaccines while the worlds poorest countries remain largely unvaccinated, according to a new analysis. The companies have sold the vast majority of their doses to rich countries, leaving low-income nations in the lurch, said the Peoples Vaccine Alliance (PVA), a coalition campaigning for wider access to Covid vaccines, which based its calculations on the firms own earning reports. The Alliance estimates that the trio will make pre-tax profits of $34 billion this year between them, which works out to over $1,000 a second, $65,000 a minute or $93.5 million a day. It is obscene that just a few companies are making millions of dollars in profit every single hour, while just two percent of people in low-income countries have been fully vaccinated against coronavirus, Maaza Seyoum of the African Alliance and Peoples Vaccine Alliance Africa said. Pfizer, BioNTech and Moderna have used their monopolies to prioritise the most profitable contracts with the richest governments, leaving low-income countries out in the cold. Pfizer and BioNTech have delivered less than one percent of their total supplies to low-income countries while Moderna has delivered just 0.2 percent, the PVA said.

Related Stocks: VTI , FPE , CRWD , IJH , BND , IEFA , MMIT , FPXI , DNA , QTWO , SPTM , IEMG , VTA , DRNA , MUB , ALK , CCIV , BNTX ,

Related Stocks: INBX , BNTX , ADGI , VIR , FULC , AVTE , BEAM , EPIX , KROS , RLAY , GBIO ,

The Peoples Vaccine Alliance (PVA) has carried out an analysis on Pfizer, BioNTech and Moderna which suggests that the three drugmakers are making as much as $65,000 as combined profit every minute. This conclusion was based on calculations of the firms own earning reports by PVA. The profit is generated from their highly successful COVID-19 []

The procedure for the administration of a booster dose for individuals aged 40 years and over starts as of tomorrow, November 17th, provided that a period of six months has elapsed since the completion of their vaccination scheme (namely the administration of a second dose in the case of Pfizer/BioNTech, Moderna and AstraZeneca vaccines or Johnson & Johnsons []

According to a report by the People’s Vaccine Alliance, In contrast, AstraZeneca and Johnson & Johnson sell their vaccines at a cost price.

Related Stocks: GE , ADI , BNTX , EIX , CVS , GLD , MXIM , SLV , NVDA , CLX , RIO ,

For the first time since the pandemic began, BioNTech CEO Uur ahin made his way to the US, this time for a cancer drug conference in Washington, DC, last week. Prior to presenting his company''s poster on early, promising data for its CLDN6-targeted CAR-T, ahin sat down with a small

Pfizer and BioNTech are expanding business opportunities with suggestions for third shots of their vaccines. The firms are lobbying the U.S. Food and Drug Administration (FDA) to approve a third dose of COVID vaccine produced by them for every person from 18 years and above. The advisory panels to the FDA and Centers for Disease The post Pfizer expands business, places profits above public health, lobbies FDA to authorize Booster Shots for all adults appeared first on National Daily Newspaper .

Patient investors who overcome short-term distractions will get a windfall with these stocks to buy, as they're set to grow at a faster pace. The post 7 Stocks to Buy That Will Make You Rich by 2030 a

HONG KONG , Nov. 15, 2021 /PRNewswire/ -- On 15 November 2021 , the results of the third ESG Leading Enterprise Awards 2021 were announced, which was organized by the Chinese Edition of Bloomberg Businessweek in partnership with Deloitte, one of the world''s largest accounting firms, and with the support from InvestHK under the Government of the Hong Kong Special Administrative Region, Hong Kong Institute of Bankers, Hong Kong Securities and Investment Institute, and CFA Society Hong Kong. Fosun International has garnered the "ESG Leading Enterprise Award" in the Category I - Market capitalization over HK$20 billion and the "ESG Leading Social Initiative Award". The Chinese Edition of Bloomberg Businessweek stated that it partnered again with Deloitte to host the third ESG Leading Enterprise Awards to recognize Hong Kong -listed companies and asset management companies with outstanding Environmental, Social and Governance (ESG) performance. This year''s awards aimed at encouraging enterprises to adopt ESG practices strategically to cope with the "new normal" business environment and continue fostering a sustainable business culture.

Israel announced that children of age 5 to 11 will now be suitable for vaccination against coronavirus. The Health Ministry declared the decision after approval by an expert panel last week. After which, the US Food and Drug Administration (FDA) permitted emergency use of Pfizer and BioNTechs Covid-19 vaccine for The post Israel Declares 5-11 Year-Olds Eligible for Vaccination appeared first on Equitypandit .

Political messaging around the necessity of covid booster shots is once again following the “optics” script rather than the scientific script. The SARS-CoV-2 virus is a permanent addition to human

Israel on Sunday approved giving the COVID-19 vaccine to children between the ages of 5 and 11. The Health Ministry decision follows approval by U.S. health authorities earlier this month to OK the vaccine for the same age group. Israel was one of the first countries in the world to carry out a broad vaccination campaign in its adult and adolescent population early this year, and it became the first country to carry out a widespread booster campaign over the summer. Experts say Israel''s aggressive vaccination efforts have helped curb the spread of the coronavirus and bring a recent wave of the delta variant under control. But it has seen the coronavirus continue to spread among unvaccinated populations, including children. In a statement, the Health Ministry said its director general, Dr. Nachman Ash, accepted a recommendation from expert advisers to inoculate children with the Pfizer/BioNTech vaccine. It said a majority of advisers believed the benefits of the vaccine outweighed t

BioNTech SE (NASDAQ:BNTX) Stock analysts at SVB Leerink lowered their FY2021 earnings estimates for BioNTech in a report issued on Wednesday, November 10th. SVB Leerink analyst D. Graybosch now anticipates that the company will earn $44.27 per share for the year, down from their prior forecast of $47.51. SVB Leerink currently has a Market []